Brief: Valbiotis Expects Clinical Study Results For Three Active Substances In Portfolio In 2022

Valbiotis SA

06/01/2022 06:42

Jan 6 (Reuters) - Valbiotis SA  ALVAL.PA :
    * INCREASED MOMENTUM IN CLINICAL NEWSFLOW FOR MAJOR
INDICATIONS:
RESULTS EXPECTED IN 2022 FOR PREDIABETES, HYPERCHOLESTEROLEMIA
AND HIGH BLOOD PRESSURE
    * TOTUM•63/PREDIABETES: THE END OF RECRUITMENT IN Q2 2022,
WITH
RESULTS EXPECTED IN Q4 2022 FOR THE PIVOTAL PHASE II/III
REVERSE-IT STUDY AND COMPLETION OF A MODE OF ACTION CLINICAL
STUDY BY INAF
    * TOTUM•070/HYPERCHOLESTEROLEMIA: RESULTS OF PHASE II HEART
CLINICAL EFFICACY STUDY AND BIOAVAILABILITY AND MODE OF ACTION
CLINICAL STUDY (Q2 2022)
    * TOTUM•854/HIGH BLOOD PRESSURE: RESULTS OF BIOAVAILABILITY
AND
MODE OF ACTION CLINICAL STUDY (Q4 2022)
    * DETAILS ON DEVELOPMENT PLAN OF TOTUM-448 WILL BE ANNOUNCED
AT A
FUTURE TIME

Source text for Eikon:  ID:nBw9lW2NZa 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))